Citius Pharmaceuticals, Inc.
Financial highlights
| Metric | FY September 30, 2025 | FY September 30, 2024 | FY September 30, 2023 | FY September 30, 2022 | FY September 30, 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | $90,000 | $90,000 |
| Operating income | -$38.5M | -$42.0M | -$36.7M | -$33.3M | -$23.5M |
| Operating expenses | $38.5M | $42.0M | $36.7M | $33.3M | $23.5M |
| Cash from operations | -$26.6M | -$28.2M | -$29.1M | -$28.4M | -$24.3M |
| Capital expenditure | — | $28.4M | — | — | $6,938 |
| Free cash flow | — | -$56.6M | — | — | -$24.3M |
| Total assets | $130.9M | $116.7M | $103.6M | $114.0M | $142.4M |
| Total liabilities | $53.4M | $42.5M | $12.2M | $10.6M | $9.6M |
Shares outstanding 27.5M · Free float 79.0%
Annual filing data through FY ended September 30, 2025; float as of June 27, 2026.